Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous or haemodialysis use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ledraxen, a low molecular weight heparin, is used in conditions where clot formation must be prevented or treated.

- Deep vein thrombosis: reduces the risk of clot extension and recurrence. - Pulmonary embolism: helps prevent new clot formation and supports treatment of existing emboli. - Haemodialysis anticoagulation: maintains circuit patency by inhibiting clotting during dialysis sessions.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Injection site erythema or bruising. - Minor bleeding such as epistaxis or gum bleeding. - Nausea or mild abdominal discomfort. - Transient elevation of liver enzymes. - Mild thrombocytopenia.

Serious or Rare Side Effects: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with paradoxical clotting. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spinal or epidural hematoma after neuraxial procedures. - Severe liver dysfunction.

Clinicians should consider several safety measures when prescribing Ledraxen.

- Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Concomitant anticoagulants: avoid or closely monitor when used with warfarin, antiplatelet agents, or thrombolytics. - Surgery or invasive procedures: discontinue appropriately to reduce bleeding risk. - Pregnancy: use only if clearly needed, as classified Category B. - Breastfeeding: assess risk‑benefit, as limited data are available. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin may interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) can cause severe bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents increase hemorrhagic risk.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., fluoroquinolones) may enhance anticoagulant activity. - Statins, especially high‑dose simvastatin, may modestly increase bleeding tendency. - Hormonal therapies (e.g., estrogen) can affect clotting balance and require monitoring.